Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 383

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 383
---
,
regulators, business partners and other stakeholders. In addition, this structure will create efficiency in the preparation of the meeting
agendas and related Board materials as the Company’s Chief Executive Officer works directly with those individuals preparing the
necessary Board materials and is more connected to the overall daily operations of the Company. Agendas will also be prepared with the
permitted input of the full Board allowing for any concerns or risks of any individual director to be discussed as deemed appropriate.
The Board believes that the Company will benefit from this structure, and Mr. King’s continuation in the combined role of the Chairman
and President and Chief Executive Officer is in the best interest of the stockholders.

 41 

In addition, the Board does not currently have a lead
independent director. The Board has determined that this structure is the most effective leadership structure for our Company at this
time based on its size. In addition, our Audit, Compensation and Corporate Governance and Nominating Committees, which oversee critical
matters such as our accounting principles, financial reporting practices and system of disclosure controls and internal controls over
financial reporting, our executive compensation program and the selection and evaluation of our directors and director nominees, each
consist entirely of independent directors.

Board Risk Oversight

The Board does not have a standing risk management
committee, but rather administers this oversight function directly through the Board as a whole, as well as through committees of the
Board.

Code of Business Conduct and Ethics

We have adopted a code of business conduct and ethics
for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and
employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at www.mosaicie.com
under the Corporate Governance section of our Investors page. We will promptly disclose on our website (i) the nature of any amendment
to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller,
or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the
policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver.

Insider Trading Policy 

While our Code of Business Conduct and Ethics
strictly prohibits insider trading, we do not maintain insider trading policies and procedures governing the purchase, sale, and/or other
dispositions of our securities by our directors